Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and Follow-Up in Resected, EGFR-mutated NSCLC By Ogkologos - April 2, 2025 517 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an exploratory analysis of the ADAURA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR ESMO Highlights Key Issues for Patients with Cancer and Their Carers... May 27, 2025 Diagnosed 3 Weeks Before Her Wedding, She Finally Gets To Ring... October 11, 2019 FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid... November 26, 2024 Cancer Mortality Prediction for 2025 Continues to Show Favourable Trends In... April 16, 2025 Load more HOT NEWS FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative... Woman Creates Non-Toxic Nail Polish Brand After Her Mom’s Breast Cancer... Handmade Artisan Gifts For Under $30 Holiday Travel: 11 Things To Know Before Hitting The Road With...
